To complete its life cycle, HIV-1 enters the nucleus of the host cell as reverse-transcribed
viral DNA. The nucleus is a complex environment, in which chromatin is organized to …

Tyrosine-type site-specific recombinases (T-SSRs) have opened new avenues for the
predictable modification of genomes as they enable precise genome editing in heterologous …

Thirty years after the identification of HIV, a cure for HIV infection is still to be achieved.
Advances of combined antiretroviral therapy (cART) in recent years have transformed HIV …

Current antiviral therapies cannot cure hepatitis B virus (HBV) infection; successful HBV
eradication would require inactivation of the viral genome, which primarily persists in host …

Current combination antiretroviral therapies (cART) efficiently suppress HIV-1 reproduction
in humans, but the virus persists as integrated proviral reservoirs in small numbers of cells …

Introduction: The use of antiretroviral therapy has led to a significant decrease in morbidity
and mortality in HIV-infected individuals. Nevertheless, gene-based therapies represent a …

The fields of molecular genetics, biotechnology and synthetic biology are demanding ever
more sophisticated molecular tools for programmed precise modification of cell genomic …

CRISPR/Cas9 technology is currently considered the most advanced tool for targeted
genome engineering. Its sequence-dependent specificity has been explored for locus …

The human T cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that persists as a
provirus in the genome of infected cells and can lead to adult T cell leukemia (ATL) …

Objective: There is an urgent need for the development of HIV-1 genome eradication
strategies that lead to a permanent cure for HIV-1/AIDS. We previously reported that four …